Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 2 Study of Oral CEP-701 in Patients With Asymptomatic Hormone-Refractory Cancer With Rising Prostate Specific Antigen

NCT00081601 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00081601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00081601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 2 Study of Oral CEP-701 in Patients With Asymptomatic Hormone-Refractory Cancer With Rising Prostate Specific Antigen
Lead sponsor
Cephalon
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2004
Completion date
June 30, 2005
Enrollment
30
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer